Understand the source comparison
Best KLOW Dosage for Anti-Inflammatory: Research-Grade Comparison
Systemic (IBD, RA models) Subcutaneous 500–750 mcg 3× weekly 85–90% Gold standard for systemic inflammation. Consistent plasma levels, predictable NF-κB inhibition, supported by Phase 2 data Localized dermatological Topical 100–300 mcg 2× daily Local only Effe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Systemic (IBD, RA models)
- Subcutaneous
- 500–750 mcg
- 3× weekly
- 85–90%
- Gold standard for systemic inflammation. Consistent plasma levels, predictable NF-κB inhibition, supported by Phase 2 data
- Localized dermatological
- Topical
- 100–300 mcg
- 2× daily
- Local only
- Effective for surface inflammation without systemic exposure. Ideal for psoriasis, rosacea, contact dermatitis research
- Gastrointestinal-specific
- Oral
- 1500–2000 mcg
- Daily
- 15–25%
- Requires 4–5× higher dose than subcutaneous to compensate for first-pass loss. Maximizes mucosal contact in colitis models
- Acute inflammatory challenge
- 750–1000 mcg
- Single bolus
- Preemptive dosing 30–60 min before insult. Effective in endotoxin, surgical trauma, ischemia-reperfusion studies
- Chronic low-grade inflammation
- 200–400 mcg
- Lower-dose maintenance protocol. Sufficient for metabolic inflammation, adipose tissue inflammation without oversuppression